navitoclax,ruxolitinib
bayer,novartis,incyte,abbvie
['refine study', 'hcc', 'bayer']
final analysis of the prospective, observational refine study. abstract: e16114, publication only #hcc #asco23
Driving innovation in cancer care for patients.

By following this account you confirm that you are an HCP & accept our community guidelines: https://t.co/iYZUrNHHuk